Apellis Pharmaceuticals Inc (APLS) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Apellis Pharmaceuticals Inc   (NASDAQ: APLS)


Apellis Pharmaceuticals Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Apellis Pharmaceuticals Inc's ROI in the first quarter of 2026?
Apellis Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 18.23 % in its first quarter of 2026, this is above APLS's average return on investment of -61.89%.
Apellis Pharmaceuticals Inc invested over the 12 months ending in its first quarter of 2026 $731 million

ROI has improved compared to 3.25% in the fourth quarter of 2025, due to net income growth.

Within the Healthcare sector 69 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Mar 31 2026 quarter, so far to 378, from total ROI ranking in the fourth quarter of 2025 at 1334.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 7.03 % 1.05 % 4.9 % 4.22 % 7.96 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 786 740 786 612 620
Return On Investment (TTM) 18.23 % 3.25 % 6.65 % -34.83 % -32.74 %
APLS's Overall Ranking # 378 # 1334 # 1056 # 2897 # 3300
Seq. Investment Change TTM 6.04 % 1.86 % 3.32 % -4.09 % 0.11 %
Seq. Net Income Change TTM 495.27 % -50.23 % - - -
Net Income (TTM) in Millions 133 22 45 -228 -224

APLS Company Profile >> Back to APLS Roi Comparisons >> See Annual APLS Return On Investment



Return On Investment APLS's Ranking
Within: No.
Industry # 33
Sector # 70
Overall # 378

Return On Investment Statistics
High Average Low
17.94 %
-61.89 %
-121.01 %
(Mar 31 2026)   (Dec 31 2021)







Financial Statements
Apellis Pharmaceuticals Inc's I. Quarter Investments $ 786 Millions APLS's Balance sheet
Apellis Pharmaceuticals Inc's I. Quarter Income $ 19 Millions Quarterly APLS's Income Statement
APLS's Income by Division See APLS's Income by Division


APLS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 740 689 541 593 750
Y / Y Investment Growth 7.31 % 27.39 % -8.69 % -20.98 % 33.11 %
Net Income in Millions 22 -198 -529 -652 -746
Y / Y Net Income Growth - - - - -
Annual Return On Investment 3.03 % -28.71 % -97.69 % -110.05 % -99.52 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 3.03 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
APLS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for APLS's Competitors
Subscribers only: Roi for Apellis Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for APLS's Customers

Other Ratios
APLS's Roa APLS's Inventory Turnover Ratio APLS's Growth Rates APLS's Dividend Statistics
APLS's Profitability Ratios APLS's Asset Turnover Ratio APLS's Dividend Growth
APLS's Roe APLS's Valuation Ratios APLS's Financial Strength Ratios APLS's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Idexx Laboratories Inc  50.05 %
Theravance Biopharma inc   43.85 %
Elite Pharmaceuticals Inc   43.22 %
Dariohealth Corp   40.59 %
Innoviva Inc   36.71 %
Indivior Pharmaceuticals Inc   36.55 %
Eli Lilly And Company  36.13 %
Abeona Therapeutics Inc   35.03 %
Lifemd Inc   34.80 %
Acadia Pharmaceuticals Inc   34.03 %
Mettler toledo International Inc   33.62 %
Adma Biologics Inc   30.38 %
Medpace Holdings Inc   30.34 %
Spero Therapeutics Inc   29.59 %
Rafael Holdings Inc  28.08 %
Incyte Corporation  27.50 %
Carlisle Companies Incorporated  24.39 %
Iradimed Corporation  23.59 %
Catalyst Pharmaceuticals Inc   23.58 %
Engene Therapeutics Inc   22.76 %
Protalix Biotherapeutics inc   22.70 %
Electromed Inc   22.36 %
Dexcom Inc   22.17 %
Illumina Inc   22.01 %
Pro dex Inc   20.88 %
Gilead Sciences Inc   20.52 %
Vertex Pharmaceuticals Inc  20.49 %
Agilent Technologies inc   20.46 %
Zoetis Inc   20.35 %
Resmed Inc   20.23 %

Date modified: 2026-09-18T14:10:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.